Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

After a decade of relying on blood transfusions for her congenital disorder, 11-year-old Dang Thanh Mai Thu is now recovering ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent beta-thalassemia in August 2022, and exagamglogene autotemcel (exa-cel; ...

A one-day blood donation camp for thalassemia patients was held at the Municipal Corporation office on Thursday, with the joint ...

Thalassemia is a hereditary blood disorder characterised by the body's inability to produce enough haemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body.

DKMS Foundation India inaugurates new BMT unit in Ahmedabad, providing hope and treatment for thalassemia patients in Gujarat ...

A Thalassemia screening desk has been inaugurated at the NADRA centre in Sukkur on Saturday marking a significant step ...

Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners ...